Clinical trials: Systemic Lupus
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Autologous Polyclonal Tregs for Lupus
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Trial name
- NCT02428309
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
- Trial name
- NCT02472795
- Testing
- Cenerimod
- Where
- 18 sites in United States, Belarus and 4 more
- Volunteers
- 105 people
- Sponsor
- Viatris Innovation GmbH
Systemic Lupus Erythematous (SLE)
Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus
Background: The immune system is the body's defense against bacteria and other harmful invaders. In people with systemic lupus erythematosus (SLE), the immune system becomes overactive and attacks healthy cells by mistake.
- Trial name
- NCT04233164
- Testing
- Solu-Medrol 1mg/kg, Solu-Medrol 250 mg
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Background: Lupus causes a person s immune system to attack the body. It can cause blood vessel problems, heart attack, or stroke. Researchers want to see if the drug pioglitazone may help.
- Trial name
- NCT02338999
- Testing
- PET/CT, Pioglitazone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus (SLE)
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
This Phase 4 study is being performed to examine the effects of Acthar for the indicated use of treatment of SLE. This study will enroll patients with steroid-dependent, persistently active SLE with arthritic and/or cutaneous…
- Trial name
- NCT01753401
- Testing
- Acthar, Steroid Drug
- Where
- 22 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mallinckrodt
Lupus Nephritis
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.
- Trial name
- BLISS-LN (NCT01639339)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 448 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.
- Trial name
- NCT00732940
- Testing
- Belimumab 100 mg SC
- Where
- 11 sites in United States, Mexico
- Volunteers
- 56 people
- Sponsor
- Human Genome Sciences Inc.
Systemic Lupus Erythematosus, Quality of Life
Peer Approaches to Lupus Self-management
The Peer Approaches to Lupus Self-Management (PALS) study is a randomized, controlled in which 360 African American women with lupus will be recruited from the MUSC SLE database (60 mentors and 300 mentees).
- Conditions
- Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
- Trial name
- PALS (NCT03734055)
- Testing
- Peer Mentoring, Social Support Group
- Where
- United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Lupus Erythematosus, Systemic, Atrioventricular Block
Systemic Lupus Erythematous and Heart Conduction Disorders
Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus erythematous (SLE).
- Conditions
- Lupus Erythematosus, Systemic, Atrioventricular Block, Sudden Death
- Trial name
- NCT02162992
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 151 people
- Sponsor
- Germans Trias i Pujol Hospital
Lupus Erythematosus, Systemic
Women Empowered to Live With Lupus Study
The purpose of this research is to examine whether the Chronic Disease Self-management Program (CDSMP) would improve health outcomes and reduce health care use in African American women with systemic lupus erythematosus (SLE).
- Trial name
- WELL (NCT02988661)
- Testing
- Chronic Disease Self-management Program (CDSMP)
- Where
- United States
- Volunteers
- 699 people
- Sponsor
- Emory University
Lupus Erythematosus, Lupus Nephritis
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
- Trial name
- EQUALISE (NCT04128579)
- Testing
- Itolizumab [Bmab 600]
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 52 people
- Sponsor
- Biocon Limited
Lupus Nephritis
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
The aim of the open multi-center study is to determine an efficient and safe dose and dosing schedule of NKT-01 in induction of response in treatment of lupus nephritis.
- Trial name
- NCT00709722
- Testing
- NKT-01
- Where
- 6 sites in Czechia, Germany
- Volunteers
- 21 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Systemic Lupus Erythematosus, Connective Tissue Disease
On Open-Label Study in Participants With Systemic Lupus Erythematosus
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Trial name
- Illuminate-X (NCT01488708)
- Testing
- LY2127399
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Eli Lilly and Company
Lupus Erythematosus, Systemic
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants.
- Trial name
- RECAST SLE (NCT04925934)
- Testing
- VIB7734
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 214 people
- Sponsor
- Amgen
Lupus Nephritis
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in…
- Trial name
- NCT00377637
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences using the intervention during…
- Trial name
- NCT05426902
- Testing
- SLE@Duke
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Active Systemic Lupus Erythematosus
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic…
- Trial name
- NCT02446912
- Testing
- Anifrolumab
- Where
- 145 sites in United States, Argentina and 16 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- EMBODY2 (NCT01261793)
- Testing
- Epratuzumab
- Where
- 133 sites in United States, Brazil and 14 more
- Volunteers
- 791 people
- Sponsor
- UCB Pharma